MIND Act of 2025

Bill Number

S. 2925

Origin Chamber

Senate

Congress

119th Congress, Session 1

Policy Area

Commerce

Status

Introduced

Latest Action

2025-09-29: Read twice and referred to the Committee on Commerce, Science, and Transportation. (text: CR S6834-3836)

Last Updated

2025-12-16T19:03:57Z

AI-Generated Summary

Summary of S. 2925: Management of Individuals' Neural Data Act of 2025 (MIND Act of 2025)

Purpose

The legislation aims to address emerging risks from neural data—information about brain and nerve activity collected via neurotechnology (devices or methods that monitor or influence the nervous system)—and related data like biometrics or behavior patterns that can reveal mental states. It directs the Federal Trade Commission (FTC) to study how to govern this data for privacy, security, and ethical use, while limiting federal agencies' use of such technologies until proper safeguards are established. The goal is to protect personal autonomy, prevent misuse, and foster responsible innovation in neurotechnology without stifling progress.

Key Provisions

• Sense of Congress: Declares concerns over how neural and related data can be monetized to influence behavior, emotions, and decisions; highlights risks from corporate consolidation in tech, AI, and data systems; emphasizes needs for privacy protections, civil liberties, and national security; and notes similar risks from biometric or behavioral data that infers mental states.

• Definitions:
• Neural data: Information from measuring an individual's central or peripheral nervous system using neurotechnology.
• Neurotechnology: Tools or methods to access, monitor, record, analyze, predict, stimulate, or alter the nervous system.
• Other related data: Biometric, physiological, or behavioral info (e.g., heart rate, eye tracking, voice analysis) that can infer cognitive, emotional, or psychological states when processed.
• References existing definitions for AI and federal agencies.

• FTC Study and Report:
• FTC must conduct a comprehensive study on needed federal authorities for regulating neural and related data, best practices for private-sector privacy and security, and gaps in current laws (e.g., HIPAA, which covers health data privacy).
• Consultations required with the Office of Science and Technology Policy (OSTP), FDA, other agencies, and stakeholders like private sector, academia, civil society, consumer advocates, labor, patients, and healthcare professionals.
• Report due to Congress within 1 year of enactment; must be published online. It proposes a regulatory framework balancing innovation with risks like discrimination, surveillance, and manipulation.
• Report Contents (detailed analysis and recommendations on):
• Collection, processing, storage, sale, transfer, and uses of data for influencing mental states or behavior.
• Ethical, legal, and regulatory landscape, including consent, individual rights, and predictive modeling.
• Benefits (e.g., improving quality of life, advancing neuroscience) vs. risks (e.g., to vulnerable groups in various contexts).
• Categorization framework for data based on benefits/harms, sensitivity, and governance needs (e.g., stricter consent, prohibited uses, cybersecurity).
• AI integration risks and standards for brain models.
• Safeguards against unfair practices like coercive marketing.
• Sector-specific recommendations (e.g., employment, education especially for children/teens, insurance, neuromarketing, law enforcement, data brokers).
• Applicability of existing FTC laws and gaps in child privacy protections (e.g., COPPA).
• Security risks: Cybersecurity gaps, export controls, foreign investment, supply chains, cloud vs. local storage.
• Incentives for ethical innovation: Tax credits, regulatory sandboxes (testing environments with oversight), procurement preferences, public-private partnerships, FDA/CMS coordination for approvals.
• Enforcement framework: Penalties, remedies for misuse or negligence.
• Other FTC-determined topics.

• Annual Updates: FTC must update and publicize the report yearly to track neurotechnology advances and privacy needs.

• Funding: Authorizes $10 million for the study and related activities.

• Limitations on Federal Agency Use:
• Within 180 days of the FTC report, OSTP (with FTC and OMB input) develops non-binding guidance on agency procurement and use of neurotechnology involving neural/related data. Covers prohibited/permissible uses, safeguards, transparency, consent, and privacy.
• OMB issues binding guidance to agencies within 60 days.
• Agencies prohibited from procuring or using such neurotechnology inconsistently with the guidance; effective 1 year after OMB issuance.

Significant Changes to Existing Law

• Introduces the first federal mandate for a dedicated study on neural data governance, filling gaps in laws like HIPAA (which protects health data but may not cover all neural uses) and FTC consumer protection statutes.
• Establishes annual reporting requirements to adapt to rapid tech changes, unlike static existing frameworks.
• Imposes conditional prohibitions on federal agencies' use of neurotechnology, creating new oversight not previously specified in procurement or privacy laws.
• Expands consideration of AI and neurotech intersections, potentially leading to new standards beyond current AI initiatives (e.g., National AI Initiative Act).

Potential Impacts

• Government Agencies: FTC gains resources and authority to lead on neural data; OSTP and OMB must create enforceable guidelines, restricting agency adoption of neurotech (e.g., in surveillance or healthcare) until safeguards are met. Could slow federal innovation but enhance ethical compliance.
• Citizens: Stronger potential privacy protections against data misuse in daily life (e.g., advertising, hiring), reducing risks of manipulation or discrimination. Vulnerable groups (e.g., children, patients) may benefit from targeted safeguards, though implementation depends on future regulations.
• International Relations: Addresses national security by scrutinizing foreign investments, exports, and supply chains in neurotech; promotes U.S. standards for data transfers, potentially influencing global norms and reducing risks from foreign access to sensitive U.S. data assets.

Main Stakeholders Affected

• Individuals and Consumers: Primary beneficiaries/protected parties, especially those using wearables, AI devices, or medical neurotech; impacts privacy in employment, education, finance, and commerce.
• Private Sector: Neurotechnology companies, AI firms, data brokers, wearables makers (e.g., in healthcare, marketing); must adapt to recommended best practices, consent rules, and potential restrictions on data resale or uses.
• Government Entities: FTC (leads study), OSTP/OMB (guidance), FDA/CMS (approvals/coordination), other agencies (procurement limits); broader federal involvement in tech oversight.
• Civil Society and Advocacy Groups: Consumer, patient, labor, and privacy organizations; involved in consultations and could influence enforcement.
• Academia and Researchers: Benefit from incentives like funding and sandboxes for ethical studies, but face new ethical guidelines.
• International Actors: Foreign investors and governments; affected by U.S. security recommendations on tech transfers.

Notable Legal, Constitutional, or Political Implications

• Legal: Could lead to new privacy laws or FTC enforcement tools, bridging gaps in HIPAA/COPPA for non-medical neural data; emphasizes consent and prohibitions on certain uses, aligning with broader data protection trends but raising questions on enforceability without specific rules.
• Constitutional: Reinforces privacy rights under the Fourth Amendment (unreasonable searches) and First Amendment (free thought/behavior), by limiting surveillance/manipulation; balances innovation with civil liberties, potentially sparking debates on federal overreach in private tech.
• Political: Bipartisan sponsorship (e.g., Schumer, Cantwell, Markey) signals consensus on tech privacy; may influence future bills on AI/neurotech regulation, promoting U.S. leadership amid global competition (e.g., EU data laws). Risks politicization if recommendations target specific industries, but focuses on public trust and equity to mitigate disparities.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Schumer, Charles E. [D-NY]

Cosponsors (2)

Sen. Cantwell, Maria [D-WA], Sen. Markey, Edward J. [D-MA]

Recent Actions

• 2025-09-29: Read twice and referred to the Committee on Commerce, Science, and Transportation. (text: CR S6834-3836)
• 2025-09-29: Introduced in Senate

Bill Versions

• Management of Individuals’ Neural Data Act of 2025 — issued 2025-09-29 — PDF (18 pages)